These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 14722939)

  • 41. 8-years experience of fluoroquinolone susceptibility testing of multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand.
    Prammananan T; Chaiprasert A; Leechawengwongs M
    Int J Antimicrob Agents; 2011 Jan; 37(1):84-5. PubMed ID: 21075609
    [No Abstract]   [Full Text] [Related]  

  • 42. First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran--eight years of surveillance.
    Shamaei M; Marjani M; Chitsaz E; Kazempour M; Esmaeili M; Farnia P; Tabarsi P; Amiri MV; Mirsaeidi M; Mansouri D; Masjedi MR; Velayati AA
    Int J Infect Dis; 2009 Sep; 13(5):e236-40. PubMed ID: 19285897
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
    Jindani A; Aber VR; Edwards EA; Mitchison DA
    Am Rev Respir Dis; 1980 Jun; 121(6):939-49. PubMed ID: 6774638
    [No Abstract]   [Full Text] [Related]  

  • 44. Could Killing Bacterial Subpopulations Hit Tuberculosis out of the Park?
    Baranowski C; Rubin EJ
    J Med Chem; 2016 Jul; 59(13):6025-6. PubMed ID: 27322073
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Principles of the antitubercular therapy].
    Bojalil LF
    Gac Med Mex; 1975 Jul; 110(1):63-6. PubMed ID: 807497
    [No Abstract]   [Full Text] [Related]  

  • 46. Reversion of phenotypic fluoroquinolone resistance in Mycobacterium tuberculosis.
    Eilertson B; Maruri F; Blackman A; Herrera M; Sterling TR
    Int J Tuberc Lung Dis; 2016 Sep; 20(9):1276-7. PubMed ID: 27510259
    [No Abstract]   [Full Text] [Related]  

  • 47. Anti-tuberculosis drug resistance in new and previously treated pulmonary tuberculosis cases in Burkina Faso.
    Sangaré L; Diandé S; Badoum G; Dingtoumda B; Traoré AS
    Int J Tuberc Lung Dis; 2010 Nov; 14(11):1424-9. PubMed ID: 20937182
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tuberculosis drug resistance in an area of low endemicity in 2004 to 2006: semiquantitative drug susceptibility testing and genotyping.
    Springer B; Calligaris-Maibach RC; Ritter C; Böttger EC
    J Clin Microbiol; 2008 Dec; 46(12):4064-7. PubMed ID: 18923010
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Drug therapy of mycobacterial infections from the viewpoint of a bacteriologist].
    Urbanczik R
    Prax Klin Pneumol; 1982 Mar; 36(3):135-40. PubMed ID: 6808492
    [No Abstract]   [Full Text] [Related]  

  • 50. Trench warfare in a battle with TB.
    Marshall E
    Science; 2008 Jul; 321(5887):362-4. PubMed ID: 18635790
    [No Abstract]   [Full Text] [Related]  

  • 51. [Short-term chemotherapy of tuberculosis in Chile. Bacteriological considerations].
    Valenzuela P
    Rev Med Chil; 1983 Jul; 111(7):747-9. PubMed ID: 6440255
    [No Abstract]   [Full Text] [Related]  

  • 52. Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results.
    Migliori GB; Lange C; Girardi E; Centis R; Besozzi G; Kliiman K; Ortmann J; Matteelli A; Spanevello A; Cirillo DM;
    Clin Infect Dis; 2008 Mar; 46(6):958-9. PubMed ID: 18288911
    [No Abstract]   [Full Text] [Related]  

  • 53. [Sparfloxacin in combined therapy for pulmonary tuberculosis].
    Sokolova GB; Khaĭmenova TIu; Lazareva IaV; Khaĭmenov AIa
    Antibiot Khimioter; 2008; 53(5-6):21-7. PubMed ID: 19069178
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Proportion of drug resistance among relapse tuberculosis cases --summary of Ryoken studies 1977-2002].
    Yoshiyama T
    Kekkaku; 2009 Dec; 84(12):778-80. PubMed ID: 20196276
    [No Abstract]   [Full Text] [Related]  

  • 55. Children and multidrug-resistant tuberculosis in Mumbai (Bombay), India.
    Karande S; Bavdekar SB
    Emerg Infect Dis; 2002 Nov; 8(11):1360-1. PubMed ID: 12453371
    [No Abstract]   [Full Text] [Related]  

  • 56. Multiple drug-resistant Mycobacterium tuberculosis: evidence for changing fitness following passage through human hosts.
    Gillespie SH; Billington OJ; Breathnach A; McHugh TD
    Microb Drug Resist; 2002; 8(4):273-9. PubMed ID: 12523624
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy.
    Miotto P; Piana F; Penati V; Canducci F; Migliori GB; Cirillo DM
    J Clin Microbiol; 2006 Jul; 44(7):2485-91. PubMed ID: 16825369
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The achievements of the fundamental sciences and new approaches in the chemotherapy of tuberculosis].
    Egorov AM
    Probl Tuberk; 2000; (5):11-5. PubMed ID: 11077844
    [No Abstract]   [Full Text] [Related]  

  • 59. [Multidrug-resistant tuberculosis].
    Abe C
    Nihon Rinsho; 2003 Mar; 61 Suppl 3():202-6. PubMed ID: 12717972
    [No Abstract]   [Full Text] [Related]  

  • 60. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure.
    Wang JY; Lee LN; Lai HC; Wang SK; Jan IS; Yu CJ; Hsueh PR; Yang PC
    J Antimicrob Chemother; 2007 May; 59(5):860-5. PubMed ID: 17412727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.